The Law Offices of Frank R. Cruz announces an investigation of Replimune Group Inc. (“Replimune” or the “Company”) (NASDAQ: REPL) on behalf of investors concerning the Company’s possible violations of federal securities laws.

What Is The Investigation About?
On July 28, 2026, the US Food and Drug Administration (“FDA”) released briefing documents related to Replimune’s lead trial for its drug vusolimogene oderparepvec, or RP1, for skin cancer. The briefing documents state the FDA has deemed the single-arm mid-stage study submitted by Replimune to support the approval of the drug as “not interpretable.” The assessment used in the study “confounds interpretation of the reported efficacy results and limits FDA’s ability to verify the reported results,” the FDA reviewers said.

On this news, Replimune’s stock price fell $3.27, or 37.89% in intraday trading on July 28, 2026, thereby injuring investors.